Advertisement

U.S. markets closed

S&P Futures
4,048.25
-7.50(-0.18%)
Dow Futures
32,530.00
-70.00(-0.21%)
Nasdaq Futures
12,251.75
-27.50(-0.22%)
Russell 2000 Futures
1,834.10
-2.20(-0.12%)
Crude Oil
114.03
-0.06(-0.05%)
Gold
1,851.70
+4.10(+0.22%)

Advertisement

WEF 2022

Yahoo Finance is in Davos! Get the latest updates here

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

7.80

+0.03

(+0.39%)

At close: 04:00PM EDT

8.05

+0.25

(+3.21%)

After hours:

07:59PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	7.77
Open	7.81
Bid	7.79 x 3000
Ask	8.80 x 900
Day's Range	7.76 - 8.03
52 Week Range	6.54 - 49.51
Volume	186,313
Avg. Volume	297,906

Market Cap	331.589M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.94
Earnings Date	May 10, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	69.60

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CMPS

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

COMPASS Pathways Plc - American
FLGT: Raising target price to $45.00FULGENT GENETICS INC has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
Rating
Fair Value
Economic Moat
9 days agoArgus Research

All

GlobeNewswire
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Hear Professor David Hellerstein talk about the study Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the Ameri
Simply Wall St.
Could The COMPASS Pathways plc (NASDAQ:CMPS) Ownership Structure Tell Us Something Useful?
The big shareholder groups in COMPASS Pathways plc ( NASDAQ:CMPS ) have power over the company. Insiders often own a...
- What You Need To Know About FactSet Research Systems Inc.'s (NYSE:FDS) Investor Composition
  Simply Wall St.
- Here's What Advanced Drainage Systems, Inc.'s (NYSE:WMS) Shareholder Ownership Structure Looks Like
  Simply Wall St.
GlobeNewswire
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: Citi’s Biopharma Virtual Co-Panel Day: panel “Mood Disorders/Mental Health Panel” at 11:00 am ET on 18 May 2022HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022 A live audio webcast of